异维A酸治疗接受男性化激素治疗的跨性别者痤疮
本多中心回顾性病例系列研究纳入55例接受男性化性别肯定激素治疗并因痤疮使用异维A酸的患者,中位疗程6个月、中位累积剂量132.7 mg/kg;87.3%改善、47.3%清除,累积剂量≥120 mg/kg者改善率达97.0%、清除率63.6%,常见不良反应为干燥,但提前停药常见且与较差结局相关。
要点
- 异维A酸对接受男性化激素治疗的跨性别者痤疮常有效且耐受良好。
- 累积剂量≥120 mg/kg者改善率97.0%、清除率63.6%,高于总体。
- 提前停药常见,与成本、药房、不良反应及手术愈合顾虑相关。
核心结论
- 在接收男性化性别肯定激素治疗并接受异维A酸治疗的痤疮患者中,异维A酸常有效且耐受良好,但提前停药常见并与较差结局相关。
研究设计与样本
- 多中心回顾性病例系列研究,纳入4个医学中心12至49岁接受男性化性别肯定激素治疗并因痤疮使用异维A酸的患者55例。
主要发现
- 55例患者平均(SD)年龄25.4岁,异维A酸中位疗程6个月(IQR 4.0-8.0),中位累积剂量132.7 mg/kg(IQR 66.4-168.5)。
- 48例(87.3%)改善,26例(47.3%)清除;累积剂量≥120 mg/kg的33例中改善32例(97.0%)、清除21例(63.6%)。
- 20例达到清除且有后续就诊者中复发风险为20.0%(n=4)。
- 最常见不良反应为干燥(n=44;80.0%)、关节痛(n=8;14.5%)、湿疹(n=5;9.1%),实验室异常不常见。
关键数值与推荐
- 累积剂量低于90 mg/kg者16例(29.1%),低于120 mg/kg者22例(40.0%)。
- 提前停药原因包括费用、药房问题、不良反应、后勤原因(日程安排)及性别肯定手术的伤口愈合顾虑。
临床怎么用
- 对接受男性化激素治疗的跨性别痤疮患者,异维A酸可作为有效选择,但需关注累积剂量与提前停药风险。
- 临床应识别并处理费用、药房、不良反应及手术愈合顾虑等停药障碍以改善结局。
局限性
- 回顾性病例系列设计,样本量55例,结果需在更大样本中验证。
- 原文未报告对照组及长期随访数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Masculinizing gender-affirming hormonal therapy is associated with the development of acne. While isotretinoin is a highly effective acne treatment, little is known about its effectiveness and safety among transgender and gender-diverse individuals receiving gender-affirming hormonal therapy. OBJECTIVE: To evaluate clinical outcomes of isotretinoin among transgender and gender-diverse individuals receiving gender-affirming hormonal therapy. DESIGN, SETTING, AND PARTICIPANTS: This multicenter retrospective case series study was conducted at 4 medical centers: Mass General Brigham, University of Pennsylvania, Emory University, and Fenway Health. It included patients aged between 12 and 49 years who were receiving masculinizing gender-affirming hormonal therapy and prescribed isotretinoin for the management of acne between August 14, 2015, and September 20, 2023. EXPOSURE: Isotretinoin therapy for the management of acne. MAIN OUTCOMES AND MEASURES: The percentage of patients experiencing improvement or clearance of acne, as well as rates of acne recurrence. Adverse effects and reasons for treatment discontinuation were also evaluated. RESULTS: Among 55 included patients, the mean (SD) age was 25.4 years; 4 (7.3%) were Asian, 2 (3.6%) were Black, 4 (7.2%) were Hispanic, 1 was (1.8%) multiracial, and 36 (65.5%) were White. The median isotretinoin course duration was 6 months (IQR, 4.0-8.0), with a median cumulative dose of 132.7 mg/kg (IQR, 66.4-168.5); the cumulative dose was less than 90 mg/kg for 16 patients (29.1%) and less than 120 mg/kg for 22 patients (40.0%). Isotretinoin was associated with improvement in 48 patients (87.3%) and clearance in 26 patients (47.3%). For the 33 patients treated with a cumulative dose of 120 mg/kg or more, these rates increased to 32 patients (97.0%) and 21 patients (63.6%), respectively. Among the 20 patients who achieved acne clearance and had any subsequent health care encounters, the risk of recurrence was 20.0% (n = 4). The most frequently reported adverse effects were dryness (n = 44; 80.0%), joint pain (n = 8; 14.5%), and eczema (n = 5; 9.1%). Laboratory abnormalities were uncommon. Reasons for premature treatment discontinuation included cost, pharmacy issues, adverse effects, logistical reasons (scheduling), and wound healing concerns for gender-affirming surgery. CONCLUSION AND RELEVANCE: In this case series study of individuals with acne who were receiving masculinizing gender-affirming hormonal therapy and underwent isotretinoin treatment, isotretinoin was often effective and well tolerated. However, premature treatment discontinuation was common and associated with poorer outcomes. Further efforts are needed to understand optimal dosing and treatment barriers to improve outcomes in transgender and gender-diverse individuals receiving masculinizing gender-affirming hormonal therapy.
引用
- Choe J, Shields A, Ferreira A, et al. Isotretinoin for Acne in Transgender and Gender-Diverse Individuals Receiving Masculinizing Hormone Therapy. JAMA Dermatol. 2024. PMID: 38809569. doi:10.1001/jamadermatol.2024.1420
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。